Skip to content

Depreciation at other companies

AbbVie logo
AbbVieABBV
Sana Biotechnology logo
Sana BiotechnologySANA
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s depreciation?
Immix Biopharma, Inc. (IMMX) reported depreciation of $91.58K in Q1 2026.
How has Immix Biopharma, Inc.'s depreciation changed year-over-year?
Immix Biopharma, Inc.'s depreciation increased by 140.0% year-over-year, from $38.15K to $91.58K.
What is the long-term trend for Immix Biopharma, Inc.'s depreciation?
Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s depreciation has grown at a 215.9% compound annual growth rate (CAGR), from $2.47K to $245.75K.